Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Elicio Therapeutics's share price for the quarter that ended in Mar. 2024 was €6.85. Elicio Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 10.22 Mil. Therefore, Elicio Therapeutics's market cap for the quarter that ended in Mar. 2024 was €70.01 Mil.
Elicio Therapeutics's quarterly market cap
stayed the same
from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) but then
increased
from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€70.01 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Elicio Therapeutics's Enterprise Value for Today is €75.86 Mil.
Elicio Therapeutics Market Cap Historical Data
The historical data trend for Elicio Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Elicio Therapeutics's Market Cap
For the Biotechnology subindustry, Elicio Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicio Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Elicio Therapeutics's Market Cap falls into.
Elicio Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Elicio Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicio Therapeutics (FRA:9HA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Elicio Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Elicio Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Elicio Therapeutics (FRA:9HA) Business Description
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:9HA has been successfully added to your 